Company Genome & Company

Stocks

A314130

KR7314130006

Biotechnology & Medical Research

End-of-day quote Korea S.E. 2026-10-26			5-day change	1st Jan Change
3,890.00 ^KRW	-0.38%		-10.37%	-43.46%

09-20	Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index	CI
08-14	Genome & Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Business description: Genome & Company

Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.

Number of employees: 96

Sales by Activity: Genome & Company

Fiscal Period: December	2021 (KRW)	2022 (KRW)	2023 (KRW)	2024 (KRW)	2025 (KRW)
Pharmaceuticals	451M	14.08B	14.3B	27.74B	24.59B

See all business segments

Geographical breakdown of sales: Genome & Company

Fiscal Period: December	2021 (KRW)	2022 (KRW)	2023 (KRW)	2024 (KRW)	2025 (KRW)
South Korea	451M	14.08B	14.3B	6.3B	13.37B
Asia	-	-	-	4.43B	5.95B
North America	-	-	-	9.6B	4.44B
Europe	-	-	-	7.37B	785M
South America	-	-	-	29.46M	31.13M
Oceania	-	-	-	10.96M	13.71M

See all geographic segments

Executive Committee: Genome & Company

Manager	Title	Age	Since
Han-Su Park CEO	Chief Executive Officer	53	2015-09-23
Ji-Soo Bae CEO	Chief Executive Officer	55	2015-09-23

See GENOME & COMPANY governance

Composition of the Board of Directors: Genome & Company

Director	Title	Age	Since
Ji-Soo Bae BRD	Director/Board Member	55	2015-09-23
Han-Su Park BRD	Director/Board Member	53	2015-09-23
Yu-Seok Hong BRD	Director/Board Member	62	-
Soo-Hyun Park BRD	Director/Board Member	39	2026-03-29
Gyu-Yeon Lee BRD	Director/Board Member	63	2025-03-27
Jae-Yeon Park BRD	Director/Board Member	50	2025-03-27
Eun-Ha Kim BRD	Director/Board Member	52	2026-03-29

Composition of the Board of Directors

Shareholders: Genome & Company

Name	Stocks	%	Valuation
Han-Su Park 6.285 %	3,286,760	6.285 %	12 M ₩
Ji-Soo Bae 5.852 %	3,060,640	5.852 %	12 M ₩
DSC Investment, Inc. (Venture Capital) 4.477 %	2,341,202	4.477 %	9 M ₩
InterVest Co., Ltd. 4.464 %	2,334,628	4.464 %	9 M ₩
Paratus Investment, Inc. 2.765 %	1,446,248	2.765 %	5 M ₩

List of GENOME & COMPANY shareholders

Company details: Genome & Company

Genome & Co.

7th 8th Floor, 50 Changryong-daero

13486, Seongnam-si

http://www.genomecom.co.kr

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOME & COMPANY	-0.38%	-10.37%	+41.20%	-32.23%	154M
WUXI APPTEC CO., LTD.	+0.88%	-0.34%	+40.64%	+73.05%	64.69B
ARGENX SE	-0.26%	+6.91%	+11.14%	+77.36%	54.78B
LONZA GROUP AG	+0.47%	+3.52%	+8.22%	+100.95%	53.49B
IQVIA HOLDINGS INC.	-2.06%	+2.90%	+24.07%	+48.36%	45.98B
BEONE MEDICINES AG	-1.79%	+0.19%	+19.32%	+123.62%	42.94B
REVOLUTION MEDICINES, INC.	-1.65%	+0.96%	+237.56%	+823.66%	40.08B
CELLTRION, INC.	-2.26%	-4.14%	+15.38%	+45.53%	33.52B
WUXI BIOLOGICS (CAYMAN) INC.	-3.18%	-11.25%	+19.15%	-6.97%	23.97B
GENMAB A/S	+12.10%	+16.60%	+55.14%	+46.15%	23.67B
Average	+0.18%	+0.37%	+47.18%	+129.95%	38.33B
Weighted average by Cap.	-0.10%	+1.62%	+45.46%	+149.64%